Haematology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for Irish Healthcare Professionals only

      Information and Downloads

      Here are downloadable resources for both healthcare professionals and patients

      HCP Resources

      Educational Modules

      {{noResultsFoundText}}

      {{downloadLibraryItem.fileTitle}}

      {{downloadLibraryItem.fileDescription}}

      {{itemTag.name}}

      Load More

      HCP Dosing and Administration Guides

      {{noResultsFoundText}}

      {{downloadLibraryItem.fileTitle}}

      {{downloadLibraryItem.fileDescription}}

      {{itemTag.name}}

      Load More

      tex

      gettingstarted

      Patient Resources  

      {{noResultsFoundText}}

      {{downloadLibraryItem.fileTitle}}

      {{downloadLibraryItem.fileDescription}}

      {{itemTag.name}}

      Load More

      tex

      gettingstarted

      Patient Videos

      Venclyxto Monotherapy CLL 
      Venclyxto + Obinutuzumab CLL 
      Venclyxto + Rituximab CLL

      CLL=chronic lymphocytic leukaemia; 2L+=second line + later lines of therapy; HR=hazard ratio; CI=confidence interval; PFS=progression-free survival; BR=bendamustine + rituximab; VEN+R=VENCLYXTO® + rituximab.

      I want to find out more about VENCLYXTO® in CLL

      Why Venclyxto

      Reference: 1. VENCLYXTO® Summary of Product Characteristics, available at www.medicines.ie 

       

      IE-VNCCLL-230073 | Date of preparation: December 2023

      CLICK HERE FOR FULL VENCLYXTO® (venetoclax) PRESCRIBING INFORMATION
      Our therapy areas
      Haematology
      Neurology
      Additional info
      Privacy Policy
      Terms and Conditions

       

      Reporting an Adverse Event: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Health Products Regulatory Authority (HPRA) Pharmacovigilance. www.hpra.ie.

       

      This website is intended for Irish Healthcare Professionals only
      Copyright© 2024 AbbVie Inc.

      Unless otherwise specified, all product names appearing in this internet site are trademarks owned or licensed by AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade names or trade dress in this site may be made without the prior written authorisation of AbbVie Inc., except to identify the product or services of the company

      AbbVie Pro is developed and funded by AbbVie Limited

      AbbVie Limited, a private company limited by Shares, and a member of the AbbVie group of companies.

      Registered in Ireland with Company Number 510846.

      Local contact details: 14 Riverwalk, Citywest Business Campus, Dublin 24, D24 XN32, Ireland. Tel (0) 1 4287900. www.abbvie.ie

      Date of Preparation: July 2022 | IE-ABBV-220078